Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Thoracic 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 438Triple Negative Breast Neoplasms 50Neoplasm Metastasis 24Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 22Colorectal Neoplasms 18Carcinoma, Intraductal, Noninfiltrating 18Neoplasms 16Pancreatic Neoplasms 14Prostatic Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 12Colonic Neoplasms 11Breast Neoplasms, Male 10Urinary Bladder Neoplasms 8Small Cell Lung Carcinoma 8Melanoma 8Fatigue 8Breast Carcinoma In Situ 8Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lymphedema 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Cancer Female 6Testicular Neoplasms 5Pain 5Esophageal Neoplasms 5

Interventions

Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liposarcoma × Breast × Clear all
NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡